Olalekan Ajayi, PharmD, MBA, 2023-2024 president of the Association of Community Cancer Centers, discusses what practices should do to succeed under the Enhancing Oncology Model (EOM).
Olalekan Ajayi, PharmD, MBA, 2023-2024 president of the Association of Community Cancer Centers (ACCC), discusses several factors practices should have and questions they need to ask themselves if they are to succeed under the Enhancing Oncology Model (EOM) after the Oncology Care Model (OCM).
Transcript
What factors do you believe are most important for practices to succeed under the EOM, whether or not they participated in the OCM?
I think the first thing with EOM that most people are thinking about is, how is it going to impact my practice? One of the main things that other practices are beginning to do, particularly those who have been in the OCM—but if you're not an OCM practice, you can do this, too, as well—is better understanding the data around your population that you're managing, and being able to layer it on what it might look like if you are an EOM practice.
So if you're building that kind of model, what does that look like for me in my practice? And what are the things that we need to do in our practice to be successful? We have the opportunity right now to look at our existing data and to be able to layer it in that model. The second thing I would say is, when it comes to designing workflows within the practice, how can we design a workflow that makes us succeed? A good example is with patient-reported outcomes. How do we design a workflow around that that makes us successful as a practice and also helps us meet those requirements with EOM?
We are at a very exciting time in cancer care. We have new emerging technologies that are going to take us to places far beyond our imagination, which is really great. One of the things that I would always say is that as we begin to leverage these technologies, we need to think about not only developing our workforce, but how these technologies are going to impact access to care. So we need to be very mindful that people don't get left behind in implementing these new technologies. So I'm looking forward to being a part of that solution at ACCC. We are the how-to organization, and so that's what we've always done best.
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More